Trial Profile
A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemochromatosis; Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 05 Sep 2014 New trial record